FIRST-IN-CLASS
DRUG TREATMENTS
Lin BioScience is focused on discovering and developing innovative
drug candidate for the treatment of cancer and eye diseases
ORAL DRUG TREATMENT
for MACULAR DEGENERATION
First-in-Class oral therapeutic candidate for Dry Age-related Macular Degeneration and Stargardt Disease
TARGET THERAPY
with BROAD ONCOLOGY APPLICATIONS
Natural small molecular inhibitor for treatment of broad variety of cancers
NEWS
Sep 18 , 2018 FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease Designation enhances FDA orphan drug designation for Phase I candidate targeting incurable blindness in children.
Jun 28 , 2018 Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease Phase I drug candidate targeting disease that causes blindness in children receives second orphan drug designation.
Apr 25 , 2018 Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
PIPELINE
Discovery
Preclinical
Phase1
Phase2
008
Dry AMD Stargardt Disease
007
Acute Leukemia Solid Tumors
009
NASH Type 2 Diabetes
002
Glioblastoma Brain Metastasis
Dry AMD
Stargardt Disease
Acute Leukemia
Solid Tumors
NASH
Type 2 Diabetes
Glioblastoma
Brain Metastasis